Oppenheimer analyst Rupesh Parikh said the health of Walmart’s (NYSE:WMT) business looks stronger than the company expected, with larger grocery store share growth, healthy growth in other revenue streams and tighter controls on capital spending. The analyst believes that management’s 2-2.5% sales growth guidance for Walmart in the United States is conservative given its stronger expectations for food inflation, the potential for continued share growth, and the high-single-digit sales growth momentum until 2022. With standards reset and the company’s favorable fundamental view, the bank re-added Walmart to the list of best options after multiple quarters. He has an outperform rating on the stock with a $160 price target.